Skip to main content
SpringerLink
Log in

Evaluation of crystallographic orientation of biological apatite in vertebral cortical bone in ovariectomized cynomolgus monkeys treated with minodronic acid and alendronate

  • Short Communication
  • Published:
Journal of Bone and Mineral Metabolism Aims and scope Submit manuscript

Abstract

Quantitative analysis of the orientational distribution of biological apatite (BAp) crystals is proposed as a new index of bone quality. This study aimed to analyze BAp c-axis orientation in ovariectomized (OVX) monkeys treated with amino-bisphosphonates minodronic acid and alendronate as reference. Sixty female monkeys aged 9–17 years were divided into five groups: one sham group and four OVX groups. The sham group and one OVX group were treated daily with vehicle for 17 months. The other three groups were treated daily with minodronic acid at doses of 0.015 and 0.15 mg/kg, and alendronate at 0.5 mg/kg orally, respectively. The seventh lumbar vertebrae were subjected to analysis of the preferential BAp c-axis orientation in the ventral cortical bone. The BAp c-axis orientation along the craniocaudal axis was significantly increased in the OVX monkeys. The high dose of minodronic acid suppressed the OVX-induced increase in the BAp c-axis orientation, whereas alendronate showed a non-significant tendency to suppress the increase in the orientation. In analysis with other parameters, the BAp c-axis orientation was positively correlated with bone formation indices in biochemical markers and bone histomorphometry and negatively correlated with the increase in lumbar bone mineral density. On the other hand, the BAp c-axis orientation was not correlated with bone resorption indices, except for the eroded surface. These results indicate that the increase in BAp c-axis orientation was ameliorated by minodronic acid treatment in OVX monkeys, mainly by suppression of bone formation increase.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

References

  1. Osteoporosis Prevention, Diagnosis, and Therapy (2001) NIH consensus development panel on osteoporosis prevention, diagnosis, and therapy. JAMA 285:785–795

    Article  Google Scholar 

  2. Delmas PD (2002) Treatment of postmenopausal osteoporosis. Lancet 8:2018–2026

    Article  Google Scholar 

  3. Russell RG (2011) Bisphosphonates: the first 40 years. Bone 49:2–19

    Article  CAS  PubMed  Google Scholar 

  4. Ohno K, Mori K, Orita M, Takeuchi M (2011) Computational insights into binding of bisphosphates to farnesyl pyrophosphate synthase. Curr Med Chem 18:220–233

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Hagino H, Nishizawa Y, Sone T, Morii H, Taketani Y, Nakamura T, Itabashi A, Mizunuma H, Ohashi Y, Shiraki M, Minamide T, Matsumoto T (2009) A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis. Bone 44:1078–1084

    Article  CAS  PubMed  Google Scholar 

  6. Okazaki R, Hagino H, Ito M, Sone T, Nakamura T, Mizunuma H, Fukunaga M, Shiraki M, Nishizawa Y, Ohashi Y, Matsumoto T (2012) Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis. Osteoporos Int 23:1737–1745

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, Ohashi Y, Nakamura T, Matsumoto T (2012) Three years of treatment with minodronate in patients with postmenopausal osteoporosis. J Bone Miner Metab 30:439–446

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Tanaka M, Mori H, Kayasuga R, Ochi Y, Kawada N, Yamada H, Kishikawa K (2008) Long-term minodronic acid (ONO-5920/YM529) treatment suppresses increased bone turnover, plus prevents reduction in bone mass and bone strength in ovariectomized rats with established osteopenia. Bone 43:894–900

    Article  CAS  PubMed  Google Scholar 

  9. Mori H, Tanaka M, Kayasuga R, Masuda T, Ochi Y, Yamada H, Kishikawa K, Ito M, Nakamura T (2008) Minodronic acid (ONO-5920/YM529) prevents decrease in bone mineral density and bone strength, and improves bone microarchitecture in ovariectomized cynomolgus monkeys. Bone 43:840–848

    Article  CAS  PubMed  Google Scholar 

  10. Burr D (1992) Estimated intracortical bone turnover in the femur of growing macaques: implications for their use as models for skeletal pathology. Anat Rec 232:180–189

    Article  CAS  PubMed  Google Scholar 

  11. Jerome CP, Turner CH, Lees CJ (1997) Decreased bone mass and strength in ovariectomized cynomolgus monkeys (Macaca fascicularis). Calcif Tissue Int 60:265–270

    Article  CAS  PubMed  Google Scholar 

  12. Jerome CP, Peterson PE (2001) Nonhuman primate models in skeletal research. Bone 29:1–6

    Article  CAS  PubMed  Google Scholar 

  13. Kostenuik PJ, Smith SY, Jolette J, Schroeder J, Pyrah I, Ominsky MS (2011) Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody. Bone 49:151–161

    Article  CAS  PubMed  Google Scholar 

  14. Jerome C, Missbach M, Gamse R (2012) Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys. Osteoporos Int 23:339–349

    Article  CAS  PubMed  Google Scholar 

  15. Smith SY, Recker RR, Hannan M, Müller R, Bauss F (2003) Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. Bone 32:45–55

    Article  CAS  PubMed  Google Scholar 

  16. Itoh F, Kojima M, Furihata-Komatsu H, Aoyagi S, Kusama H, Komatsu H, Nakamura T (2002) Reductions in bone mass, structure, and strength in axial and appendicular skeletons associated with increased turnover after ovariectomy in mature cynomolgus monkeys and preventive effects of clodronate. J Bone Miner Res 17:534–543

    Article  CAS  PubMed  Google Scholar 

  17. Nightingale JP, Lewis D (1971) Pole figures of the orientation of apatite in bones. Nature 232:334–335

    Article  CAS  PubMed  Google Scholar 

  18. Landis WJ (1995) The strength of a calcified tissue depends in part on the molecular structure and organization of its constituent mineral crystals in their organic matrix. Bone 16:533–544

    Article  CAS  PubMed  Google Scholar 

  19. Sasaki N, Sudoh Y (1997) X-ray pole figure analysis of apatite crystals and collagen molecules in bone. Calcif Tissue Int 60:361–367

    Article  CAS  PubMed  Google Scholar 

  20. Elliot JC (1994) Structure and chemistry of the apatites and other calcium orthophosphates, 1st edn. Elsevier Science, Amsterdam

    Google Scholar 

  21. Nakano T, Kaibara K, Tabata Y, Nagata N, Enomoto S, Marukawa E, Umakoshi Y (2002) Unique alignment and texture of biological apatite crystallites in typical calcified tissues analyzed by microbeam X-ray diffractometer system. Bone 31:479–487

    Article  CAS  PubMed  Google Scholar 

  22. Ishimoto T, Nakano T, Umakoshi Y, Yamamoto M, Tabata Y (2013) Degree of biological apatite c-axis orientation rather than bone mineral density controls mechanical function in bone regenerated using recombinant bone morphogenetic protein-2. J Bone Miner Res 28:1170–1179

    Article  CAS  PubMed  Google Scholar 

  23. Nakano T, Kaibara K, Ishimoto T, Tabata Y, Umakoshi Y (2012) Biologicalapatite (BAp) crystallographic orientation and texture as a new index for assessing the microstructure and function of bone regenerated by tissue engineering. Bone 51:741–747

    Article  PubMed  Google Scholar 

  24. Shiraishi A, Miyabe S, Nakano T, Umakoshi Y, Ito M, Mihara M (2009) The combination therapy with alfacalcidol and risedronate improves the mechanical property in lumbar spine by affecting the material properties in an ovariectomized rat model of osteoporosis. BMC Musculoskelet Disord 10:66

    Article  PubMed  PubMed Central  Google Scholar 

  25. Yoshida Y, Moriya A, Kitamura K, Inazu M, Okimoto N, Okazaki Y, Nakamura T (1998) Responses of trabecular and cortical bone turnover and bone mass and strength to bisphosphonate YH529 in ovariohysterectomized beagles with calcium restriction. J Bone Miner Res 13:1011–1022

    Article  CAS  PubMed  Google Scholar 

  26. Balena R, Toolan BC, Shea M, Markatos A, Myers ER, Lee SC, Opas EE, Seedor JG, Klein H, Frankenfield D (1993) The effects of 2-year treatment with the amino bisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest 92:2577–2586

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Noyama Y, Nakano T, Ishimoto T, Sakai T, Yoshikawa H (2013) Design and optimization of the oriented groove on the hip implant surface to promote bone microstructure integrity. Bone 52:659–667

    Article  CAS  PubMed  Google Scholar 

  28. Müller R, Hannan M, Smith SY, Bauss F (2004) Intermittent ibandronate preserves bone quality and bone strength in the lumbar spine after 16 months of treatment in the ovariectomized cynomolgus monkey. J Bone Miner Res 19:1787–1796

    Article  PubMed  Google Scholar 

  29. Yamagami Y, Mashiba T, Iwata K, Tanaka M, Nozaki K, Yamamoto T (2013) Effects of minodronic acid and alendronate on bone remodeling, micro damage accumulation, degree of mineralization and bone mechanical properties in ovariectomized cynomolgus monkeys. Bone 54:1–7

    Article  CAS  PubMed  Google Scholar 

  30. Ebetino FH, Hogan AM, Sun S, Tsoumpra MK, Duan X, Triffitt JT, Kwaasi AA, Dunford JE, Barnett BL, Oppermann U, Lundy MW, Boyde A, Kashemirov BA, McKenna CE, Russell RG (2011) The relationship between the chemistry and biological activity of the bisphosphonates. Bone 49:20–33

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors thank Satoshi Nishikawa and Hiroshi Mori for their technical assistance in this study.

Conflict of interest

M Tanaka is a research scientist at Ono Pharmaceutical Co., Ltd. All other authors state no conflict of interest, except that measurement of the BAp c-axis orientation was funded by Ono Pharmaceutical Co., Ltd. Minodronic acid was launched by Ono Pharmaceutical Co., Ltd. and Astellas Pharma Inc. in Japan.

Author information

Authors and Affiliations

  1. Research Promotion, Ono Pharmaceutical Co., Ltd., 3-1-1 Sakurai, Shimamoto, Osaka, 618-8585, Japan

    Makoto Tanaka

  2. Division of Materials and Manufacturing Science, Graduate School of Engineering, Osaka University, Suita, Osaka, 565-0871, Japan

    Aira Matsugaki, Takuya Ishimoto & Takayoshi Nakano

Authors
  1. Makoto Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aira Matsugaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takuya Ishimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takayoshi Nakano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Makoto Tanaka.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tanaka, M., Matsugaki, A., Ishimoto, T. et al. Evaluation of crystallographic orientation of biological apatite in vertebral cortical bone in ovariectomized cynomolgus monkeys treated with minodronic acid and alendronate. J Bone Miner Metab 34, 234–241 (2016). https://doi.org/10.1007/s00774-015-0658-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00774-015-0658-2

Keywords

Search

Navigation